Back to Results
First PageMeta Content
Harboes Bryggeri / Saxo Bank


Bavarian Nordic Annual Report 2014
Add to Reading List

Document Date: 2015-03-11 02:39:05

Open Document

File Size: 1,39 MB

Share Result on Facebook

Company

Appeal / Johnson & Johnson / Consolidated Key Figures DKK / Janssen 22 Growth Opportunities / Bavarian Nordic Inc. / Technology Platforms 14 Our Manufacturing / Significant Milestones 2014 / IMVAMUNE 20 Ebola Partnership / Tax Income / Crucell Holland B.V. / Bristol-Myers Squibb / Glaxosmithkline plc / /

Country

Canada / Denmark / /

Currency

USD / DKK / /

Event

FDA Phase / Earnings Announcement / M&A / Employment Change / Funding / Natural Disaster / Business Partnership / Patent Issuance / /

Facility

facility of DKK / University of Oxford / National Cancer Institute / U.S. National Institute of Allergy / /

IndustryTerm

manufacturing vaccines / manufacturing line / validated manufacturing process / /

MedicalCondition

smallpox / bladder cancer / prostate cancer / freeze-dried IMVAMUNE smallpox / additional infectious disease / Ebola / solid tumor / advanced cancer / diseases / Infectious Diseases / /

MedicalTreatment

immunotherapy / /

Organization

National Cancer Institute / Board of Appeal / U.S. Government / Canadian Government / Danish government / University of Oxford / GSK / U.S. National Institute of Allergy and Infectious Diseases / European Patent Office / European Union / /

Person

Asger Aamund / Paul Chaplin / Gerard van Odijk / Significant Milestones / Anders Hedegaard / /

Position

member of the board / CEO / Chairman / Annual Report Independent Auditor / President & CEO / chairman of the board / board member / /

Product

July Bavarian / July Bavarian Nordic’s MVA-BN® vaccine platform / CV-301 / PROSTVAC / MVA-BN® Brachyury / cAd3-EBO / /

SocialTag